




Egyptian Society of Rheumatic Diseases
The Egyptian Rheumatologist

www.rheumatology.eg.net
www.elsevier.com/locate/ejr



ORIGINAL ARTICLE

Immunological profile and dyslipidemia in Egyptian Systemic Lupus Erythematosus patients

Sherif M. Gamal^a, Samar M. Fawzy^{a,*}, Marwa Abdo^a, Fatema T. Elgengehy^a, Shada Ghoniem^a, Alkhateeb Alkemry^b

^a Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Egypt

^b Internal Medicine Department, Faculty of Medicine, Cairo University, Egypt

Received 27 April 2016; accepted 12 May 2016

KEYWORDS

Immune profile;
 Anti-Ro;
 Dyslipidemia;
 SLE;
 SLEDAI

Abstract *Aim of the work:* To study the relation of the immune profile to dyslipidemia in a cohort of Egyptian Systemic Lupus Erythematosus (SLE) patients.

Patients and methods: This study included 221 SLE patients with a disease duration > 6 months at study entry. Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) and severity using the Systemic Lupus International Collaborating Clinics/Damage Index (SLICC/DI). Patients were investigated for the anti-nuclear antibody (ANA), anti-double stranded deoxy-ribonucleic acid (anti-dsDNA), anti-cardiolipin (ACL) antibodies (IgG and IgM), anti Ro (SSA) and anti La (SSB). Dyslipidemia was considered if the high density lipoproteins (HDL), low density lipoproteins (LDL), total cholesterol (TC) or triglycerides (TG) were abnormal.

Results: The mean age of the patients was 28.8 ± 7.8 years and the median disease duration was 5 years. The clinical manifestations of the patients were pleurisy (52.9%), pericarditis (24.9%), nephritis (68.3%), CNS lupus (23.1%), vasculitis (14.9%) and musculoskeletal manifestations (57.9%). All patients were on corticosteroids (median dose 35 mg/day; range 5–80 mg/day), while 92 (43.4%) of them received cyclophosphamide during their disease course. The mean SLEDAI was 12.1 ± 7.4 and SLICC/DI was 1.4 ± 1.6 . Patients with positive anti-Ro ($n = 44$; 19.9%) showed statistically significant lower level of HDL ($p = 0.01$).

Conclusion: Positive anti-Ro may be associated with increased incidence of low HDL in lupus patients which in turn may increase the incidence of cardiovascular accidents.

© 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author. Tel.: +20 1001805126.

E-mail address: samarfawzy1@yahoo.com (S.M. Fawzy).

Peer review under responsibility of Egyptian Society for Rheumatic Diseases.



Production and hosting by Elsevier

1. Introduction

It is proved that Dyslipidemias are being increasingly recognized as an important cause of development of cardiovascular disease (CVD) [1]. An increase of 1% in total cholesterol causes 2% increase in the incidence of ischemic heart disease

<http://dx.doi.org/10.1016/j.ejr.2016.05.007>

1110-1164 © 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: Gamal SM et al. Immunological profile and dyslipidemia in Egyptian Systemic Lupus Erythematosus patients, The Egyptian Rheumatologist (2016), <http://dx.doi.org/10.1016/j.ejr.2016.05.007>

Table 1 Laboratory data of the Systemic Lupus Erythematosus patients.

Parameter	<i>n</i> (%) or median (range)	SLE patients (<i>n</i> = 221)	
<i>Immune profile</i>			
Positive test	Anti-ANA	212	(95.9)
	Anti-ds DNA	150	(67.9)
	ACL	71	(32.1)
	Anti Ro	44	(19.9)
	Anti La	14	(6.3)
<i>Lipid profile</i> (mg/dL)			
High TG		79	(35.7)
High cholesterol		113	(51.1)
High LDL		67	(30.3)
Risk (low) HDL		99	(44.8)
Hb (mg/dL)		10.5	(4.5–15.9)
TLC ($\times 10^3$)		6.9	(1.4–26.3)
PLT ($\times 10^3$)		272	(11–690)
ESR (mm/1st h)		61.0	(5–150)
ALT (IU/L)		21.0	(6–508)
Creatinine (mg/dL)		0.75	(0.2–6.2)
Proteinuria (mg/24 h)		0.83	(0–5.9)
C3 (mg/dL)		80	(98–178)
C4 (mg/dL)		15	(1–130)

SLE: Systemic Lupus Erythematosus, ANA: antinuclear antibodies, dsDNA: double stranded deoxy-ribonucleic acid, ACL: anti-cardiolipin, Hb hemoglobin, TLC: total leukocytic count, ESR: erythrocyte sedimentation rate, ALT: alanine transaminase, C: complement.

(IHD) [2]. In fact atherosclerotic cardiovascular diseases (ASCVD) are also the leading cause of morbidity and mortality in various autoimmune diseases, mainly rheumatoid arthritis, antiphospholipid syndrome (APS) and Systemic Lupus Erythematosus (SLE) [3,4]. SLE is a complex autoimmune disease characterized by immune disturbances and involvement of multiple systems and organs. Dyslipidemia in Egyptian SLE patients was reported to be associated with decreased quality of life and damage accrual with an increased risk of atherosclerosis [5].

Although the survival of SLE patients has improved during the past three decades; however, they still die at a rate that is three times higher than that of the general population [6] while early deaths could be explained by active disease and infection, late deaths (patients aged > 40 years) are mainly attributed to CVD [7,8]. Recent advances in the etiology of accelerated atherosclerosis in SLE have stressed the relevance of the interplay between lupus-specific inflammatory factors and traditional cardiac risk factors in causing increased endothelial damage [9].

The presence of autoantibodies is a cardinal feature of SLE [10]. Quantification on the serum levels and/or prevalence of one or more autoantibodies recently demonstrated their significance in the disease pathology [11]. Anti-double stranded deoxy-ribonucleic acid (anti-dsDNA) antibodies were significantly associated with lupus nephritis (LN) [12,13] and both anti-Ro and anti-La antibodies were strongly associated with skin manifestations [14] in SLE patients.

Thus the aim of the current study was to investigate the relation of SLE associated autoantibodies and dyslipidemia in a cohort of Egyptian patients.

2. Patients and methods

The study, descriptive and cross-sectional, included 221 Egyptian SLE patients fulfilling the updated ACR revised criteria for the classification of SLE [15]. All the patients had the disease duration more than 6 months at study entry. The patients were attending the Rheumatology department of Cairo University Hospitals during 2014.

All Patients were subjected to full history taking, thorough clinical examination, laboratory and relevant radiological investigations were performed for all the patients. Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) [16] and severity using the Systemic Lupus International Collaborating Clinics/Damage Index (SLICC/DI) [17].

The clinical manifestations are described based on the SLEDAI and SLICC items. The study has been approved by local ethics committee and it conforms to the standards currently applied in Cairo University Teaching Hospitals. Patients gave an informed consent before being enrolled in the study.

The information collected included the history of smoking, alcohol intake, presence of diabetes mellitus, and dose of steroid. A detailed dietary history was also included.

For all patients, serological examinations were performed including the following: (A) Immune profile: Anti-nuclear antibody and anti-ds DNA tests were carried out by indirect Immunofluorescence (IIF) technique; anti-cardiolipin antibodies (ACL) (IgG and IgM) and anti-Ro (SSA) and Anti-La (SSB) were detected by ELISA. (B) Lipid profile: high density lipoproteins (HDL), low density lipoproteins (LDL), total cholesterol (TC) and triglycerides (TG) were checked. A diagnosis of dyslipidemia was given if the patient had (a) hypercholesterolemia, defined as taking lipid-lowering medication as a surrogate, or having a fasting plasma TC ≥ 200 mg/dL (b) HDL ≤ 40 mg/dL, (c) hypertriglyceridemia (TG ≥ 150 mg/dL) or (d) elevated LDL (≥ 100 mg/dL) [18].

Statistical analysis: Data were statistically described in terms of range, mean \pm standard deviation (SD), median, frequencies (number of cases) and percentages when appropriate. Comparison of quantitative variables between the study groups was done using Mann–Whitney U-test for independent samples. For comparing categorical data, Chi-square (χ^2) test was performed. Exact test was used instead when the expected frequency is less than 5. A probability value (p value) less than 0.05 was considered statistically significant. All statistical calculations were done using computer programs Microsoft Excel 2003 (Microsoft Corporation, NY, USA) and SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows.

3. Results

This study included 221 SLE patients, 212 (95.9%) females and 9 males (4.1%). Their ages ranged from 17 to 54 years with a mean of 28.8 ± 7.8 years. Their disease duration ranged from 0.5 to 20 years with a median of 5 years. The main clinical presentation of our patients included pleurisy (52.9%), pericarditis (24.9%), nephritis (68.3%), CNS lupus (23.1%), vasculitis (14.9%), and musculoskeletal manifestations (57.9%). None of our patients had history of smoking, alcohol intake or presence of diabetes mellitus. All of our patients were on corticosteroids, their doses ranged from 5 to 80 mg/day

Table 2 Comparison between lipid profile in those with positive vs negative auto-antibodies (ANA, anti-ds DNA and ACL) in SLE patients.

Parameter <i>n</i> (%)	Systemic Lupus Erythematosus patients (<i>n</i> = 221)								
	ANA			Anti-ds DNA			ACL		
	–ve	+ ve	<i>p</i>	–ve	+ ve	<i>p</i>	–ve	+ ve	<i>p</i>
<i>TG</i>									
Normal	7 (4.9)	135 (95.1)	0.38	48 (33.8)	94 (66.2)	0.47	99 (69.7)	43 (30.3)	0.43
High	2 (2.5)	77 (97.5)		23 (29.1)	56 (70.9)		51 (64.6)	28 (35.4)	
<i>Chol.</i>									
Normal	5 (4.6)	103 (95.4)	0.68	39 (36.1)	69 (63.9)	0.21	70 (64.8)	38 (35.2)	0.34
High	4 (3.5)	109 (96.5)		32 (28.3)	81 (71.7)		80 (70.8)	33 (29.2)	
<i>LDL</i>									
Normal	5 (3.2)	149 (96.8)	0.34	48 (31.2)	106 (68.8)	0.64	105 (68.2)	49 (31.8)	0.88
High	4 (6)	63 (94)		23 (34.3)	44 (65.7)		45 (67.2)	22 (32.8)	
<i>HDL</i>									
Risk	3 (3)	96 (97)	0.48	29 (29.3)	70 (70.7)	0.41	65 (65.7)	34 (34.3)	0.56
Normal	6 (4.9)	116 (95.1)		42 (34.4)	80 (65.6)		85 (69.7)	37 (30.3)	

ANA: antinuclear antibodies, dsDNA: double stranded deoxy-ribonucleic acid, ACL: anticardiolipin, TG: triglycerides, Chol: cholesterol, LDL: low density lipoprotein, HDL: high density lipoprotein.

Table 3 Comparison between lipid profile in those with positive vs negative anti-Ro and anti-La in SLE patients.

Parameter <i>n</i> (%)	Systemic Lupus Erythematosus patients (<i>n</i> = 221)					
	Anti-Ro			Anti-La		
	–ve	+ ve	<i>p</i>	–ve	+ ve	<i>p</i>
<i>TG</i>						
Normal	114 (80.3)	28 (19.7)	0.92	132 (93)	10 (7)	0.56
High	63 (79.7)	16 (20.3)		75 (94.9)	4 (5.1)	
<i>Chol.</i>						
Normal	91 (84.3)	17 (15.7)	0.13	99 (91.7)	9 (8.3)	0.23
High	86 (76.1)	27 (23.9)		108 (95.6)	5 (4.4)	
<i>LDL</i>						
Normal	122 (79.2)	32 (20.8)	0.62	143 (92.9)	11 (7.1)	0.46
High	55 (82.1)	12 (17.9)		64 (95.5)	3 (4.5)	
<i>HDL</i>						
Risk	72 (72.7)	27 (27.3)	0.01	92 (92.9)	7 (7.1)	0.69
Normal	105 (86.1)	17 (13.9)		115 (94.3)	7 (5.7)	

TG: triglycerides, Chol: cholesterol, LDL: low density lipoprotein, HDL: high density lipoprotein.

with a median of 35 mg/day, while 92 (43.4%) of them received Cyclophosphamide during their disease course. Laboratory data of the SLE patients are shown in Table 1.

The level of SLEDAI ranged between 0 and 34 (mean: 12.1 ± 7.4) and that of the SLICC was between 0 and 8 (mean: 1.4 ± 1.6), however no statistically significant difference was found regarding both indices and any of lipid profile variables.

On comparing those with positive and negative immune profile as regards the abnormalities in triglyceride, cholesterol, LDL and HDL, patients with positive anti-Ro were found to have significantly lower HDL ($p = 0.01$); otherwise no significant statistical difference was found as shown in Tables 2 and 3.

4. Discussion

Systemic Lupus Erythematosus is the classic of systemic autoimmune diseases characterized by the production of a broad spectrum of autoantibodies [19]. Lupus autoantibodies are correlated with the occurrence of specific clinical symptoms and patients with a negative autoantibody profile had fewer clinical and laboratory features of their disease compared to those with a positive profile [20]. Antinuclear antibodies, such as anti-ds DNA, antiribosomal P, anti-Sm, anti-ribonucleoprotein (anti-RNP) and even anti-Sjögren's syndrome (SS)-B/La antibodies not only act against specific nuclear antigens but also cross-react with different surface-expressed

cognate molecules. The binding of autoantibodies to the cell surface leads to their penetration into the cell's interior to elicit cellular damage [19].

It is now well established that cerebrovascular events, myocardial infarction and subclinical atherosclerosis are increasingly recognized as serious complications of SLE [21]. Dyslipidemia is a significant comorbidity of lupus patients with multiple negative effects on the long term [22].

It is well recognized that dyslipidemia with low HDL raised TGs, unchanged or only slightly elevated LDL; is typical of SLE, especially in active disease, and this lipid pattern has been described as the "lupus pattern of dyslipoproteinemia," but the underlying mechanisms are not well known [23]. There is multifactorial origin of the dyslipidemia existing in SLE patients. So the aim of the present study was to investigate if there is any relation between SLE associated autoantibodies and the abnormal lipid profile in Egyptian SLE patients.

Our findings were consistent with the findings of Toms and coworker [24] and Khairy and her colleagues [25] as they reported that increased frequency of dyslipidemia with raised triglycerides decreased HDL-cholesterol concentration could be seen frequently in SLE patients.

Positive Anti Ro antibodies increases the risk of developing lupus nephritis [26], thus the association of low HDL in our study with positive anti-Ro antibodies could simply be explained when we know that nephritis and 24 h urinary protein are commonly associated with premature atherosclerosis in lupus patients [9].

In conclusion, Positive anti-Ro may be associated with low level of HDL which in turn is associated with an increased risk of cardiovascular accidents in lupus patients, however further studies including a higher number of patients with multivariate analysis may be required to establish such results.

Conflict of interest

None.

References

- [1] Nisar A, Rasheed U, Aziz W, Farooqi AZ. Prevalence of dyslipidemias in autoimmune rheumatic diseases. *J Coll Phys Surg Pakistan* 2012;22(4):235–9.
- [2] Spellman CW. Strategies for optimizing lipid treatment outcomes. *J Am Osteopath Assoc* 2003;103:S12–5.
- [3] van der Burg LR, van Amelsvoort LG, Boonen A, Jansen N, Kant IJ, Landewé RB. Cardiovascular morbidity and mortality among working individuals with rheumatic disease: results from a large prospective cohort study. *J Clin Rheumatol* 2015;21(7):359–63.
- [4] Turesson C, Jacobsson LT, Matteson EL. Cardiovascular comorbidity in rheumatic diseases. *Vasc Health Risk Manag* 2008;4:605–14.
- [5] Rizk A, Gheita TA, Nassef S, Abdallah A. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. *Int J Rheum Dis* 2012;15(3):261–7.
- [6] Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A. Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. *Ann Rheum Dis* 2003;62:1066–70.
- [7] Kiani AN, Post WS, Magder LS, Petri M. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. *Rheumatology (Oxford)* 2011;50(11):2071–9.
- [8] Mankad R. Atherosclerotic vascular disease in the autoimmune rheumatologic patient. *Curr Atheroscler Rep* 2015;17(4):497.
- [9] Fadda S, Nassar H, Gamal SM, Al-azizi H. Subclinical atherosclerosis in systemic lupus erythematosus patients and its relationship to disease activity and damage indices. *Z Rheumatol* 2015;74(6):529–32.
- [10] Rahman A. Autoantibodies, lupus and the science of sabotage. *Rheumatology (Oxford)* 2004;43(11):1326–36.
- [11] Yang J, Xu Z, Sui M, Han J, Sun L, Jia X, et al. Co-positivity for anti-dsDNA, -nucleosome and -histone antibodies in lupus nephritis is indicative of high serum levels and severe nephropathy. *PLoS ONE* 2015;10(10):e0140441.
- [12] Gamal SM, Fawzy S, Siam I. Does anti-DNA positivity increase the incidence of secondary antiphospholipid syndrome in lupus patients? *Egypt Rheumatol* 2013;35:141–4.
- [13] Gilliam BE, Ombrello AK, Burlingame RW, Pepmueller PH, Moore TL. Measurement of autoantibodies in pediatric-onset systemic lupus erythematosus and their relationship with disease-associated manifestations. *Semin Arthritis Rheum* 2012;41(6):840–8.
- [14] Pradhan VD, Badakere SS, Bichile LS, Dolas MP. Antibodies to Ro/SS-A and La/SS-B in systemic lupus erythematosus and other autoimmune disorders. *J Assoc Physicians India* 2002;50:762–5.
- [15] Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012;64(8):2677–86.
- [16] Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 1992;35:630–40.
- [17] Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. *Arthritis Rheum* 1997;40:809–13.
- [18] European Association for Cardiovascular Prevention & Rehabilitation Reiner Z, Catapano AL, de Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011;32(14):1769–818.
- [19] Hsieh SC, Yu CL. Autoantibody profiling in systemic lupus erythematosus. *Curr Biomarker Find* 2013;3:55–65.
- [20] Thompson D, Juby A, Davis P. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. *Lupus* 1993;2(1):15–9.
- [21] Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. *Lupus* 2000;9:166–9.
- [22] Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? *Semin Arthritis Rheum* 2016;45:604–10.
- [23] Svenungsson E, Jensen-Ustad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. *Circulation* 2001;104(16):1887–93.
- [24] Toms TE, Panoulas VF, Kitas GD. Dyslipidemia in rheumatological autoimmune diseases. *Open Cardiovasc Med J* 2011;5:64–75.
- [25] Khairy N, Ezzat Y, Naeem N, Taha R, Wesam R. Atherosclerosis biomarkers in female systemic lupus erythematosus patients with and without cardiovascular diseases. *Egypt Rheumatol*, 2016, In Press, Corrected Proof, Available online.
- [26] Wasieck CA, Reichlin M. Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La. *J Clin Invest* 1982;69(4):835–43.